Friday, February 10, 2023
Eli Lilly & Co. announced that it intends to invest an additional US $450 million in a manufacturing facility in North Carolina's Research Triangle Park.
Eli Lilly said that the investment will lead to the creation of at least 100 new jobs, and added that the expansion will improve parenteral filling, device assembly, and packaging capacity in response to rising demand for Lilly's incretin-based diabetes treatments.
This project phase is anticipated to produce the majority of manufacturing personnel when it is fully operational in 2027. This team will create incretin therapies and medical equipment using cutting-edge technology.
In North Carolina, Lilly has invested almost US $4 billion since 2020, including US $1.7 billion for the development and expansion of its site in Research Triangle Park. Initial manufacturing at Research Triangle Park is expected to start this year, and the FDA inspections are currently being prepared for.
Since 2014, Lilly has introduced 18 new drugs to help people with illnesses including cancer and diabetes live better lives, and the company intends to introduce a number of potential new drugs in 2023. This growth will be crucial in maintaining the supply of existing Lilly medications while laying the groundwork for distributing the following generation of medicines to patients all across the world.
